The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2021Harnessing the ADAR Protein to Repair the LRRK2 Mutation Causing Parkinson's Disease
Study Rationale:
The majority of cases of inherited Parkinson’s disease (PD) are caused by a single-letter change in the gene that encodes the LRRK2 protein. The mutation, which changes a G to an... -
Analysis of Patient-Reported Outcomes from Fox Insight, 2021Using Risk Scores to Link Molecular Mechanisms to Clinical Outcomes in Parkinson's Disease
Study Rationale:
The symptoms and course of Parkinson’s disease (PD) show remarkable variation from one person to another, indicating differences in the underlying disease process that may also be... -
Target Advancement Program, 2021Developing a Protein Quality Control Mechanism as a Novel Therapy for Parkinson’s Disease
Study Rationale:
Parkinson’s disease is a disorder of protein misfolding and aggregation. It is characterized by the presence of Lewy bodies and Lewy neurites: aberrant intracellular structures... -
Target Advancement Program, 2021Validating Genetic Modifiers that Affect Disease Onset in People with LRRK2 Mutations
Study Rationale:
Mutations in the LRRK2 gene are a genetic cause of Parkinson’s disease (PD). However, the disease risk for carriers of LRRK2 mutations varies widely. Other genes — or genetic... -
Research Grant Supplement, 2021The Role of LRRK2 in the Accumulation and Spread of Tau Protein
Study Rationale:
Although most cases of Parkinson’s disease (PD) have no known genetic cause, a subset is driven by mutations in a gene called LRRK2 (leucine-rich repeat kinase 2). Further, evidence... -
Priority Biology, 2021Use of the Lipid BMP as a Surrogate Marker for LRRK2 and GCase Activity
Study Rationale:
Mutations in LRRK2 and GBA1 are common genetic risk factors for Parkinson’s disease (PD) and offer promising targets for the development of PD therapies. Identification of a...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.